Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
Executive Summary
CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.
You may also be interested in...
Opioid Packaging: Is Non-Inferiority Enough For A New Claim?
Industry exec suggests new packages need be merely no worse than the classic amber vial to gain a claim, but US FDA says packaging intended to fight abuse should be better.
Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?
Appropriations bill report includes language stating that it is 'imperative' the agency take all steps necessary to require opioid prescriber training.
Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.